| 000 | 01487 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516001516.0 | ||
| 264 | 0 | _c20110216 | |
| 008 | 201102s 0 0 eng d | ||
| 022 | _a1744-7658 | ||
| 024 | 7 |
_a10.1517/13543784.2010.517193 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRosenson, Robert S | |
| 245 | 0 | 0 |
_aVarespladib methyl in cardiovascular disease. _h[electronic resource] |
| 260 |
_bExpert opinion on investigational drugs _cOct 2010 |
||
| 300 |
_a1245-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAcetates _xadverse effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAtherosclerosis _xcomplications |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aCholesterol, LDL _xblood |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCoronary Disease _xdrug therapy |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xadverse effects |
| 650 | 0 | 4 |
_aInflammation _xphysiopathology |
| 650 | 0 | 4 | _aKeto Acids |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPhospholipases A2, Secretory _xantagonists & inhibitors |
| 700 | 1 | _aFraser, Heather | |
| 700 | 1 | _aTrias, Joaquim | |
| 700 | 1 | _aHislop, Colin | |
| 773 | 0 |
_tExpert opinion on investigational drugs _gvol. 19 _gno. 10 _gp. 1245-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/13543784.2010.517193 _zAvailable from publisher's website |
| 999 |
_c20143137 _d20143137 |
||